For many years, SelectScience® has been attending scientific conferences around the world, to bring you news covering the latest technological advancements and research breakthroughs, and highlighting new products that could aid your research. Understanding the importance of these global events in the acceleration of science, we bring highlights from live shows and conferences, such as AACR, directly to you, showcasing novel technology and advances across various scientific disciplines.
Recent shows attended by SelectScience include the American Association of Clinical Chemistry (AACC) Clinical Lab Expo and Meeting 2022, the Society for Laboratory Automation and Screening (SLAS) International Conference and Exhibition 2023, and the American Association of Cancer Research (AACR) Annual Meeting 2023. As part of our Accelerating Science Special Feature, we are looking back at highlights from these key events. Read on to experience AACR 2023 with us or explore AACC 2022 and SLAS 2023.
The AACR Annual Meeting 2023 was held April 14–19 at the Orange County Convention Center in Orlando, Florida. SelectScience attended to bring you the latest news from the conference, and covered news published by manufacturers, scientific breakthroughs, and more. Founded in 1907, the AACR is the world’s first and largest professional organization dedicated to advancing cancer research and its mission, is to prevent and cure cancer. This year’s meeting brought together scientists, physicians, healthcare professionals, survivors, patients, and advocates to discuss the most recent developments in cancer science and therapy, and celebrated the latest work from institutions all around the world.
Browse the videos below to discover the latest innovations in cancer research from the show floor as experts share their thoughts and expertise on camera. Topics discussed in these insightful video interviews include precision medicine, companion diagnostics, liquid biopsies, immunotherapy and spatial technologies.
Prof. Philip Low, Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry, Purdue University, discusses his lab's focus on developing targeted therapies for various diseases. With the goal to drive precision medicine, Low's lab uses various techniques to selectively deliver drugs to cancer cells, such as exploiting cancer cells' appetite for certain components and designing small molecules that bind to overexpressed cancer receptors.
Larry Yu and Jessie Chen of ACROBiosystems share the company's dedication to partnering with its customers in the biopharmaceutical and healthcare industries, providing an overview of its core products and GMP services that comply with global standards and federal guidelines to ensure safe and reliable materials for clinical manufacturing. Plus, hear about the launch of the new ClinMax™ product line, promising kits for low-risk, high-quality biological and clinical in vitro and companion diagnostics.
Dr. Marzia Del Re from the University of Pisa discusses her research on liquid biopsy for predictive biomarkers of resistance or response to targeted therapies in patients with solid tumors. She uses digital PCR and next-generation sequencing (NGS) for her research and suggests using digital PCR for molecular identification and diagnosis of point mutations or small insertions and deletions, and using NGS for large gene rearrangements or fusions. Del Re expects an increase in the use of digital PCR for patient monitoring during treatment and believes that assessing minimal residual disease and monitoring tumor dynamics during treatment will be the next step for liquid biopsy in the clinical setting.
In this video, Dr. Moran Amit, University of Texas MD Anderson Cancer Center, discusses his lab’s focus on cancer neuroscience and improving patient outcomes. The lab aims to extend patients’ lives and improve their quality of life by studying the interaction between the nervous system and tumors. Amit's presentation at the AACR 2023 conference focused on the quality of life in patients with oropharyngeal cancer and how nerves mediate resistance to immunotherapy.
Prof. Nicholas Navin, MD Anderson Cancer Center, discusses his research program focused on developing new genomic and spatial technologies to understand cancer progression and evolution. He highlights two studies, one involving the development of a new technology for archival single-cell DNA sequencing of breast cancer tissues to understand genomic progression. The other studying chemoresistance in triple-negative breast cancer. He also discusses the importance of multi-omic measurements and spatial technologies in understanding how different tumor cells interact and change their microenvironments during disease progression and therapeutic resistance.
Experience more of AACR 2023 in our Special Feature>>
Find more news and resources in our Accelerating Science Special Feature>>